Yttrium90-TARE with or without chemotherapy may improve survival in patients with locally advanced unresectable intrahepatic cholangiocarcinoma [PDF]
Discover OncologyPurpose The prognosis for patients with unresectable intrahepatic cholangiocarcinoma (iCCA) is poor. This retrospective observational cohort study evaluates survival outcomes in patients with unresectable iCCA after having received one of three different
Esteban Garita +6 more
doaj +2 more sources
Safety of Combination TARE and SBRT in Hepatocellular Carcinoma: A Review of Literature & Single-Center Case Series [PDF]
Current OncologyHepatocellular carcinoma (HCC) is the most common primary liver cancer. At the time of diagnosis, many HCC patients are not candidates for surgical resection and are considered for other locoregional therapies, including transarterial radioembolization ...
Bahareh Gholami +10 more
doaj +2 more sources
Transarterial radioembolization versus tyrosine kinase inhibitor in hepatocellular carcinoma with portal vein thrombosis [PDF]
Clinical and Molecular Hepatology, 2023 Background/Aims Transarterial radioembolization (TARE) has shown promising results in treating advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT). However, whether TARE can provide superior or comparable outcomes to tyrosine
Moon Haeng Hur +12 more
doaj +1 more source
Frontiers in Oncology, 2023 IntroductionAlthough transarterial radioembolization (TARE) using yttrium-90 (90Y) is a treatment option for large hepatocellular carcinoma (HCC), a fraction of patients are ineligible for TARE due to high lung shunt fraction (LSF).MethodsWe evaluated if
Sung Won Chung +16 more
doaj +1 more source
Diagnostics, 2023 Background: Transarterial Radioembolization (TARE) is an effective treatment option for both primary and secondary liver malignancies. However, challenging anatomical conditions can lead to prolonged fluoroscopy times (FT), elevated doses of ...
Constantin Ehrengut +12 more
doaj +1 more source
Yttrium-90 transarterial radioembolization for liver metastases from medullary thyroid cancer
European Thyroid Journal, 2023 Objectives: Liver metastases occur in 45% of patients with advanced metastatic medullary thyroid cancer (MTC). Transarterial radioembolization (TARE) has been proposed to treat liver metastases (LM), especially in neuroendocrine tumors.
Luciana Puleo +15 more
doaj +1 more source
TARE-Induced Pan-Immune Inflammation Value as a Prognostic Biomarker in Liver-Dominant Metastatic Colorectal Cancer. [PDF]
J Clin MedDursun B +4 more
europepmc +3 more sources
Radioembolization for the treatment of hepatocellular carcinoma [PDF]
Clinical and Molecular Hepatology, 2017 Transarterial radioembolization (TARE) with yttrium 90 (90Y), an intra-arterial procedure performed by interventional radiologists, has begun being utilized in managing hepatocellular carcinoma (HCC) in Korea. There are two available TARE products: glass
Hyo-Cheol Kim
doaj +1 more source
Segmental Yttrium-90 Radioembolization as an Initial Treatment for Solitary Unresectable HCC
The Arab Journal of Interventional Radiology, 2022 Objectives To evaluate the objective response rate (ORR), time to progression (TTP), and overall survival (OS) in patients with unresectable solitary HCC less than 5 cm who were treated with 90Y glass microspheres infused at a segmental level.
Natalie J. Rothenberger +6 more
doaj +1 more source
BMC Gastroenterology, 2023 Background Transarterial radioembolization with yttrium-90 (Y-90 TARE) microspheres therapy has demonstrated positive clinical benefits for the treatment of liver metastases from colorectal cancer (lmCRC).
JC Alonso +8 more
doaj +1 more source